Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | CPT2 | P23786 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.34 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 6/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.32 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.32 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.32 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2622472 | 0.98 | FFAR1 (0.34) | FFAR1CPT2TDP1SMPD1LPAR3 | |
| SCHEMBL6464982 | 0.94 | FFAR1 (0.41) | FFAR1CPT2TDP1SMPD1LPAR3 | |
| SCHEMBL6467870 | 0.94 | FFAR1 (0.41) | FFAR1CPT2TDP1SMPD1LPAR3 | |
| SCHEMBL6473864 | 0.92 | FFAR1 (0.40) | FFAR1CPT2TDP1SMPD1LPAR3 | |
| SCHEMBL6468999 | 0.92 | FFAR1 (0.38) | FFAR1CPT2TDP1SMPD1LPAR3 | |
| SCHEMBL3279503 | 0.85 | FFAR1 (0.34) | FFAR1CPT2TDP1SMPD1LPAR3 | |
| SCHEMBL2622474 | 0.83 | LPAR3 (0.40) | FFAR1CPT2TDP1SMPD1LPAR3 | |
| SCHEMBL6527718 | 0.82 | FFAR1 (0.32) | FFAR1CPT2TDP1S1PR4S1PR1 | |
| SCHEMBL3280332 | 0.82 | LPAR3 (0.32) | FFAR1CPT2TDP1SMPD1LPAR3 | |
| SCHEMBL2622473 | 0.81 | LPAR3 (0.37) | FFAR1CPT2TDP1SMPD1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9757407-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | UNIV PRINCETON (US) | 2016-12-01 | — | — | US | disclosed |
| US-9029413-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| US-20130065850-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-03-14 | — | — | US | disclosed |
| US-8158677-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | KADMON CORPORATION, LLC | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | GOT2, MAVS, ME3 | FFAR1 2747/4885CPT2 114/4885TDP1 1761/4885 |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | FFAR1 2747/4885CPT2 114/4885TDP1 1761/4885 |
| US-20130065850-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | FFAR1 2747/4885CPT2 114/4885TDP1 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.